Clinical trial · Observational
Identifying Biomarkers for Early Detection of Cancer in Patients With Cervical Dysplasia or Carcinoma in Situ of the Cervix
Genomics Approach to Id Novel Targets & Markers for Early Detection And Intervention In Cancer (Cervical)
NCT00601601CI-TRIAL-00006442completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Studying the genes expressed in samples of tissue from patients with abnormal cells may help doctors identify biomarkers related to cancer. PURPOSE: This clinical trial is identifying biomarkers for early detection of cancer in women with cervical dysplasia or carcinoma in situ of the cervix.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cervical Cancer | Malignant Cervical Neoplasm | CURATED_EXACT | 0.92 |
| Precancerous Condition | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (4)
- measure
- Identify and catalogue genetic alterations and protein changes associated with developmental stages of cervical cancer
- timeFrame
- Done at the completion of the study.
- measure
- Identify a ranked list of candidate genes that drive the transformation of premalignant lesions to tumors for further study and validation as molecular targets for novel early detection and treatment design
- timeFrame
- Done at the completion of the study.
- measure
- Completion of genome scans at high density and analysis of gene and protein expressions to identify recurrent genetic and protein changes in cancer
- timeFrame
- Done at the completion of the study.
- measure
- Changes clustered to specific chromosomal regions which harbor tumor suppressors or oncogenes
- timeFrame
- Done at the completion of the study.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 19 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed premalignant lesion, dysplasia, or carcinoma in situ of the cervix * Clinically documented disease * Attending Vancouver General Hospital and referred to colposcopy for loop electrocautery excision procedure (LEEP) PATIENT CHARACTERISTICS: * Not pregnant * No lack of informed consent due to language difficulty, physical and mental condition PRIOR CONCURRENT THERAPY: * No prior operation for removal of the cervix * Concurrent therapy allowed
References
Publications (0)
Data not yet available
No reference posted for this study.